Antifibrinolytic therapy and perioperative considerations

Anesthesiology

Volumn 128, Issue 3, 2018, Pages 657-670

  Levy, Jerrold H ^a   Koster, Andreas ^b   Quinones, Quintin J ^a   Milling, Truman J ^c   Key, Nigel S ^d  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; TRANEXAMIC ACID;

ADVERSE OUTCOME; ANTIINFLAMMATORY ACTIVITY; BLEEDING; BRAIN HEMORRHAGE; CLINICAL OUTCOME; FIBRINOLYSIS; HEART SURGERY; HUMAN; INJURY; LIVER SURGERY; NEUROSURGERY; ORTHOPEDIC SURGERY; PERIOPERATIVE PERIOD; POSTPARTUM HEMORRHAGE; PRIORITY JOURNAL; REVIEW; SEIZURE; THROMBOSIS; BLOOD CLOTTING DISORDER; DRUG EFFECT; OPERATIVE BLOOD LOSS; PHYSIOLOGY; PROCEDURES; TRENDS;

ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION DISORDERS; BLOOD LOSS, SURGICAL; FIBRINOLYSIS; HUMANS; PERIOPERATIVE CARE; TRANEXAMIC ACID;

EID: 85045340443     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0000000000001997     Document Type: Review

References (96)

1. Chapin JC, Hajjar KA: Fibrinolysis and the control of blood coagulation. Blood Rev 2015; 29:17-24
2. Longstaff C, Kolev K: Basic mechanisms and regulation of fibrinolysis. J Thromb Haemost 2015; 13(suppl 1):S98-105
3. Wiman B, Collen D: Molecular mechanism of physiological fibrinolysis. Nature 1978; 272:549-50
4. Ilich A, Bokarev I, Key NS: Global assays of fibrinolysis. Int J Lab Hematol 2017; 39:441-7
5. Levy JH: Antifibrinolytic therapy: New data and new concepts. Lancet 2010; 376:3-4
6. Cesarman-Maus G, Hajjar KA: Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129:307-21
7. Chandler WL: The human fibrinolytic system. Crit Rev Oncol Hematol 1996; 24:27-45
8. Pasche B, Ouimet H, Francis S, Loscalzo J: Structural changes in platelet glycoprotein IIb/IIIa by plasmin: Determinants and functional consequences. Blood 1994; 83:404-14
9. Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Tait G, Beattie WS: The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth Analg 2010; 110:21-9
10. Medcalf RL: Fibrinolysis, inflammation, and regulation of the plasminogen activating system. J Thromb Haemost 2007; 5(suppl 1):132-42
11. Syrovets T, Simmet T: Novel aspects and new roles for the serine protease plasmin. Cell Mol Life Sci 2004; 61:873-85
12. Levy JH, Greenberg C: Biology of Factor XIII and clinical manifestations of Factor XIII deficiency. Transfusion 2013; 53:1120-31
13. Bajzar L, Jain N, Wang P, Walker JB: Thrombin activatable fibrinolysis inhibitor: Not just an inhibitor of fibrinolysis. Crit Care Med 2004; 32(suppl 5):S320-4
14. Kluft C, Verheijen JH, Jie AF, Rijken DC, Preston FE, Sue-Ling HM, Jespersen J, Aasen AO: The postoperative fibrinolytic shutdown: A rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest 1985; 45:605-10
15. Moore HB, Moore EE, Gonzalez E, Chapman MP, Chin TL, Silliman CC, Banerjee A, Sauaia A: Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: The spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy. J Trauma Acute Care Surg 2014; 77:811-7; discussion 817
16. Moore EE, Moore HB, Gonzalez E, Chapman MP, Hansen KC, Sauaia A, Silliman CC, Banerjee A: Postinjury fibrinolysis shutdown: Rationale for selective tranexamic acid. J Trauma Acute Care Surg 2015; 78(6 suppl 1):S65-9
17. Moore EE, Moore HB, Gonzalez E, Sauaia A, Banerjee A, Silliman CC: Rationale for the selective administration of tranexamic acid to inhibit fibrinolysis in the severely injured patient. Transfusion 2016; 56(suppl 2):S110-4
18. Schöchl H, Frietsch T, Pavelka M, Jámbor C: Hyperfibrinolysis after major trauma: Differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma 2009; 67:125-31
19. Chapman MP, Moore EE, Ramos CR, Ghasabyan A, Harr JN, Chin TL, Stringham JR, Sauaia A, Silliman CC, Banerjee A: Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy. J Trauma Acute Care Surg 2013; 75:961-7; discussion 967
20. Theusinger OM, Levy JH: Point of care devices for assessing bleeding and coagulation in the trauma patient. Anesthesiol Clin 2013; 31:55-65
21. Raza I, Davenport R, Rourke C, Platton S, Manson J, Spoors C, Khan S, De'Ath HD, Allard S, Hart DP, Pasi KJ, Hunt BJ, Stanworth S, MacCallum PK, Brohi K: The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost 2013; 11:307-14
22. Cotton BA, Harvin JA, Kostousouv V, Minei KM, Radwan ZA, Schöchl H, Wade CE, Holcomb JB, Matijevic N: Hyperfibrinolysis at admission is an uncommon but highly lethal event associated with shock and prehospital fluid administration. J Trauma Acute Care Surg 2012; 73:365-70; discussion 370
23. Tengborn L, Blombäck M, Berntorp E: Tranexamic acid-An old drug still going strong and making a revival. Thromb Res 2015; 135:231-42
24. Kim H, Szlam F, Tanaka KA, van de Locht A, Ogawa S, Levy JH: The effects of MDCO-2010, a serine protease inhibitor, on activated clotting time in blood obtained from volunteers and cardiac surgical patients. Anesth Analg 2012; 115:244-52
25. Sundaram S, Gikakis N, Hack CE, Niewiarowski S, Edmunds LH Jr, Koneti Rao A, Sun L, Cooper SL, Colman RW: Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation. Thromb Haemost 1996; 75:76-82
26. Flight SM, Johnson LA, Du QS, Warner RL, Trabi M, Gaffney PJ, Lavin MF, de Jersey J, Masci PP: Textilinin-1, an alternative antibleeding agent to aprotinin: Importance of plasmin inhibition in controlling blood loss. Br J Haematol 2009; 145:207-11
27. Koster A, Faraoni D, Levy JH: Antifibrinolytic therapy for cardiac surgery: An update. ANESTHESIOLOGY 2015; 123:214-21
28. Mojcik CF, Levy JH: Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann Thorac Surg 2001; 71:745-54
29. Day JR, Punjabi PP, Randi AM, Haskard DO, Landis RC, Taylor KM: Clinical inhibition of the seven-transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgery. Circulation 2004; 110:2597-600
30. Levy JH, Pifarre R, Schaff HV, Horrow JC, Albus R, Spiess B, Rosengart TK, Murray J, Clark RE, Smith P: A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995; 92:2236-44
31. Spiess BD, Royston D, Levy JH, Fitch J, Dietrich W, Body S, Murkin J, Nadel A: Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion 2004; 44:1143-8
32. European Society of Anaesthesiology Task Force Reports on Place of Aprotinin in Clinical Anaesthesia: Aprotinin: Is it time to reconsider? Eur J Anaesthesiol 2015; 32:591-5
33. Nilsson IM, Andersson L, Björkman SE: Epsilon-aminocaproic acid (E-ACA) as a therapeutic agent based on 5 year's clinical experience. Acta Med Scand Suppl 1966; 448:1-46
34. Nilsson IM, Sjoerdsma A, Waldenstrom J: Antifibrinolytic activity and metabolism of 6-aminocaproic acid in man. Lancet 1960; 1:1322-6
35. McNicol GP, Douglas AS: Epsilon-aminocaproic acid and other inhibitors of fibrinolysis. Br Med Bull 1964; 20:233-9
36. Nilsson IM: Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl (R Coll Pathol) 1980; 14:41-7
37. Seymour BD, Rubinger M: Rhabdomyolysis induced by epsilon-aminocaproic acid. Ann Pharmacother 1997; 31:56-8
38. Vanneste JA, van Wijngaarden GK: Epsilon-aminocaproic acid myopathy. Report of a case and literature review. Eur Neurol 1982; 21:242-8
39. Eriksson O, Kjellman H, Pilbrant A, Schannong M: Pharmacokinetics of tranexamic acid after intravenous administration to normal volunteers. Eur J Clin Pharmacol 1974; 7:375-80
40. Andersson L, Nilsoon IM, Colleen S, Granstrand B, Melander B: Role of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA. Ann NY Acad Sci 1968; 146:642-58
41. Ducloy-Bouthors AS, Jude B, Duhamel A, Broisin F, Huissoud C, Keita-Meyer H, Mandelbrot L, Tillouche N, Fontaine S, Le Goueff F, Depret-Mosser S, Vallet B, Susen S; EXADELI Study Group: High-dose tranexamic acid reduces blood loss in postpartum haemorrhage. Crit Care 2011; 15:R117
42. Faraoni D, Carlier C, Samama CM, Levy JH, Ducloy-Bouthors AS: Efficacy and safety of tranexamic acid administration for the prevention and/or the treatment of post-partum haemorrhage: a systematic review with meta-analysis [article in French]. Ann Fr Anesth Reanim 2014; 33:563-71
43. Preston JT, Cameron IT, Adams EJ, Smith SK: Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol 1995; 102:401-6
44. Berntorp E, Follrud C, Lethagen S: No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost 2001; 86:714-5
45. Aronson DL, Chang P, Kessler CM: Platelet-dependent thrombin generation after in vitro fibrinolytic treatment. Circulation 1992; 85:1706-12
46. Eisenberg PR, Miletich JP: Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood. Thromb Res 1989; 55:635-43
47. Eisenberg PR, Miletich JP, Sobel BE, Jaffe AS: Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA). Thromb Res 1988; 50:707-17
48. Winters KJ, Santoro SA, Miletich JP, Eisenberg PR: Relative importance of thrombin compared with plasmin-mediated platelet activation in response to plasminogen activation with streptokinase. Circulation 1991; 84:1552-60
49. Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, El-Sayed H, Gogichaishvili T, Gupta S, Herrera J, Hunt B, Iribhogbe P, Izurieta M, Khamis H, Komolafe E, Marrero MA, Mejia-Mantilla J, Miranda J, Morales C, Olaomi O, Olldashi F, Perel P, Peto R, Ramana PV, Ravi RR, Yutthakasemsunt S: Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): A randomised, placebocontrolled trial. Lancet 2010; 376:23-32
50. Sukeik M, Alshryda S, Haddad FS, Mason JM: Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br 2011; 93:39-46
51. Alshryda S, Sarda P, Sukeik M, Nargol A, Blenkinsopp J, Mason JM: Tranexamic acid in total knee replacement: A systematic review and meta-analysis. J Bone Joint Surg Br 2011; 93:1577-85
52. Alshryda S, Sukeik M, Sarda P, Blenkinsopp J, Haddad FS, Mason JM: A systematic review and meta-analysis of the topical administration of tranexamic acid in total hip and knee replacement. Bone Joint J 2014; 96-B:1005-15
53. Ross J, Al-Shahi Salman R: The frequency of thrombotic events among adults given antifibrinolytic drugs for spontaneous bleeding: Systematic review and meta-analysis of observational studies and randomized trials. Curr Drug Saf 2012; 7:44-54
54. Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W: Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: A systematic review of randomized trials. Thromb Res 2009; 123:687-96
55. Molenaar IQ, Warnaar N, Groen H, Tenvergert EM, Slooff MJ, Porte RJ: Efficacy and safety of antifibrinolytic drugs in liver transplantation: A systematic review and meta-analysis. Am J Transplant 2007; 7:185-94
56. Foley JH: Plasmin(ogen) at the nexus of fibrinolysis, inflammation, and complement. Semin Thromb Hemost 2017; 43:135-42
57. Syrovets T, Jendrach M, Rohwedder A, Schüle A, Simmet T: Plasmin-induced expression of cytokines and tissue factor in human monocytes involves AP-1 and IKKbeta-mediated NF-kappaB activation. Blood 2001; 97:3941-50
58. Burysek L, Syrovets T, Simmet T: The serine protease plasmin triggers expression of MCP-1 and CD40 in human primary monocytes via activation of p38 MAPK and janus kinase (JAK)/STAT signaling pathways. J Biol Chem 2002; 277:33509-17
59. Gong Y, Hart E, Shchurin A, Hoover-Plow J: Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice. J Clin Invest 2008; 118:3012-24
60. Later AF, Sitniakowsky LS, van Hilten JA, van de Watering L, Brand A, Smit NP, Klautz RJ: Antifibrinolytics attenuate inflammatory gene expression after cardiac surgery. J Thorac Cardiovasc Surg 2013; 145:1611-6, 1616.e1-4
61. Renckens R, Weijer S, de Vos AF, Pater JM, Meijers JC, Hack CE, Levi M, van der Poll T: Inhibition of plasmin activity by tranexamic acid does not influence inflammatory pathways during human endotoxemia. Arterioscler Thromb Vasc Biol 2004; 24:483-8
62. Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL: The dose-response relationship of tranexamic acid. ANESTHESIOLOGY 1995; 82:383-92
63. Fiechtner BK, Nuttall GA, Johnson ME, Dong Y, Sujirattanawimol N, Oliver WC Jr, Sarpal RS, Oyen LJ, Ereth MH: Plasma tranexamic acid concentrations during cardiopulmonary bypass. Anesth Analg 2001; 92:1131-6
64. Dowd NP, Karski JM, Cheng DC, Carroll JA, Lin Y, James RL, Butterworth J: Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. ANESTHESIOLOGY 2002; 97:390-9
65. Sharma V, Fan J, Jerath A, Pang KS, Bojko B, Pawliszyn J, Karski JM, Yau T, McCluskey S, Wasowicz M: Pharmacokinetics of tranexamic acid in patients undergoing cardiac surgery with use of cardiopulmonary bypass. Anaesthesia 2012; 67:1242-50
66. Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M: High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg 2010; 110:350-3
67. Lecker I, Wang DS, Romaschin AD, Peterson M, Mazer CD, Orser BA: Tranexamic acid concentrations associated with human seizures inhibit glycine receptors. J Clin Invest 2012; 122:4654-66
68. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, Cooper DJ, Marasco S, McNeil J, Bussières JS, McGuinness S, Byrne K, Chan MT, Landoni G, Wallace S; ATACAS Investigators of the ANZCA Clinical Trials Network: Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med 2017; 376:136-48
69. Koster A, Levy JH: Understanding potential drug side effects: Can we translate molecular mechanisms to clinical applications? ANESTHESIOLOGY 2017; 127:6-8
70. Takagi H, Ando T, Umemoto T; All-Literature Investigation of Cardiovascular Evidence (ALICE) group: Seizures associated with tranexamic acid for cardiac surgery: A meta-analysis of randomized and non-randomized studies. J Cardiovasc Surg (Torino) 2017; 58:633-41
71. Maeda T, Sasabuchi Y, Matsui H, Ohnishi Y, Miyata S, Yasunaga H: Safety of tranexamic acid in pediatric cardiac surgery: A nationwide database study. J Cardiothorac Vasc Anesth 2017; 31:549-53
72. Roullet S, Pillot J, Freyburger G, Biais M, Quinart A, Rault A, Revel P, Sztark F: Rotation thromboelastometry detects thrombocytopenia and hypofibrinogenaemia during orthotopic liver transplantation. Br J Anaesth 2010; 104:422-8
73. Porte RJ, Molenaar IQ, Begliomini B, Groenland TH, Januszkiewicz A, Lindgren L, Palareti G, Hermans J, Terpstra OT: Aprotinin and transfusion requirements in orthotopic liver transplantation: A multicentre randomised double-blind study. EMSALT Study Group. Lancet 2000; 355:1303-9
74. Dalmau A, Sabaté A, Acosta F, Garcia-Huete L, Koo M, Sansano T, Rafecas A, Figueras J, Jaurrieta E, Parrilla P: Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg 2000; 91:29-34
75. Wu CC, Ho WM, Cheng SB, Yeh DC, Wen MC, Liu TJ, P'eng FK: Perioperative parenteral tranexamic acid in liver tumor resection: A prospective randomized trial toward a "blood transfusion"-free hepatectomy. Ann Surg 2006; 243:173-80
76. Zufferey P, Merquiol F, Laporte S, Decousus H, Mismetti P, Auboyer C, Samama CM, Molliex S: Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? ANESTHESIOLOGY 2006; 105:1034-46
77. Tan J, Chen H, Liu Q, Chen C, Huang W: A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty. J Surg Res 2013; 184:880-7
78. Li ZJ, Fu X, Xing D, Zhang HF, Zang JC, Ma XL: Is tranexamic acid effective and safe in spinal surgery? A meta-analysis of randomized controlled trials. Eur Spine J 2013; 22:1950-7
79. Churchill JL, Puca KE, Meyer E, Carleton M, Anderson MJ: Comparing σ-aminocaproic acid and tranexamic acid in reducing postoperative transfusions in total knee arthroplasty. J Knee Surg 2017; 30:460-6
80. Churchill JL, Puca KE, Meyer ES, Carleton MC, Truchan SL, Anderson MJ: Comparison of σ-aminocaproic acid and tranexamic acid in reducing postoperative transfusions in total hip arthroplasty. J Arthroplasty 2016; 31:2795-2799.e1
81. Zufferey PJ, Lanoiselée J, Chapelle C, Borisov DB, Bien JY, Lambert P, Philippot R, Molliex S, Delavenne X; investigators of the PeriOpeRative Tranexamic acid in hip arthrOplasty (PORTO) Study: Intravenous tranexamic acid bolus plus infusion is not more effective than a single bolus in primary hip arthroplasty: A randomized controlled trial. ANESTHESIOLOGY 2017; 127:413-22
82. Novikova N, Hofmeyr GJ: Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2010:CD007872
83. Roberts I, Ker K: Tranexamic acid for postpartum bleeding. Int J Gynaecol Obstet 2011; 115:220-1
84. Collaborators WT: Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): An international, randomised, double-blind, placebo-controlled trial. Lancet 2017; 389: 2105-16
85. Binz S, McCollester J, Thomas S, Miller J, Pohlman T, Waxman D, Shariff F, Tracy R, Walsh M: CRASH-2 study of tranexamic acid to treat bleeding in trauma patients: A controversy fueled by science and social media. J Blood Transfus 2015; 2015:874920
86. Chang R, Cardenas JC, Wade CE, Holcomb JB: Advances in the understanding of trauma-induced coagulopathy. Blood 2016; 128:1043-9
87. Ives C, Inaba K, Branco BC, Okoye O, Schochl H, Talving P, Lam L, Shulman I, Nelson J, Demetriades D: Hyperfibrinolysis elicited via thromboelastography predicts mortality in trauma. J Am Coll Surg 2012; 215:496-502
88. Starke RM, Connolly ES Jr, Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid H: Rebleeding after aneurysmal subarachnoid hemorrhage. Neurocrit Care 2011; 15:241-6
89. Rosenørn J, Eskesen V, Schmidt K, Rønde F: The risk of rebleeding from ruptured intracranial aneurysms. J Neurosurg 1987; 67:329-32
90. Roos Y, Rinkel G, Vermeulen M, Algra A, van Gijn J: Antifibrinolytic therapy for aneurysmal subarachnoid hemorrhage: A major update of a cochrane review. Stroke 2003; 34:2308-9
91. Baharoglu MI, Germans MR, Rinkel GJ, Algra A, Vermeulen M, van Gijn J, Roos YB: Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2013:CD001245
92. Roos Y: Antifibrinolytic treatment in subarachnoid hemorrhage: A randomized placebo-controlled trial. STAR Study Group. Neurology 2000; 54:77-82
93. Hillman J, Fridriksson S, Nilsson O, Yu Z, Saveland H, Jakobsson KE: Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: A prospective randomized study. J Neurosurg 2002; 97:771-8
94. Starke RM, Kim GH, Fernandez A, Komotar RJ, Hickman ZL, Otten ML, Ducruet AF, Kellner CP, Hahn DK, Chwajol M, Mayer SA, Connolly ES Jr: Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. Stroke 2008; 39:2617-21
95. Harrigan MR, Rajneesh KF, Ardelt AA, Fisher WS III: Shortterm antifibrinolytic therapy before early aneurysm treatment in subarachnoid hemorrhage: Effects on rehemorrhage, cerebral ischemia, and hydrocephalus. Neurosurgery 2010; 67:935-9; discussion 939-40
96. Ker K, Beecher D, Roberts I: Topical application of tranexamic acid for the reduction of bleeding. Cochrane Database Syst Rev 2013:CD010562